Clinical Trials Logo

Secondary clinical trials

View clinical trials related to Secondary.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02716766 Completed - Clinical trials for Carcinoma, Hepatocellular

Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.

NCT ID: NCT02067143 Completed - Secondary Clinical Trials

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

LAL1913
Start date: May 20, 2014
Phase: Phase 2
Study type: Interventional

This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the achievement of an early negative minimal residual disease (MRD) status. The MRD study supports a risk/MRD-oriented final consolidation phase.

NCT ID: NCT01420146 Completed - Breast Neoplasms Clinical Trials

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

IJBMNZrT003
Start date: August 2011
Phase: Phase 1
Study type: Interventional

Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.